文献速递消化系统肿瘤

识别转移性结直肠癌患者药物早期疗效指标——循环肿瘤细胞、18F-氟脱氧葡萄糖正电子发射断层显像与RECIST标准的前瞻性评估

Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria.
PubMed 文献 · Ann Oncol · 2017-01-01

本研究前瞻性评估转移性结直肠癌一线化疗患者中,基线与化疗后4-6周PET-CT和循环肿瘤细胞(CTC)早期反应(双终点)的预测与预后意义,10-12周CT评估RECIST反应。双终点早期反应与无进展生存期独立相关(HR=0.452,95%CI 0.267-0.765),RECIST反应与总生存期独立相关(HR=0.484,95%CI 0.275-0.852)。

要点

  • 双终点早期反应(PET-CT SUVmax总和下降30%且CTC<3个/7.5ml血)与PFS独立相关,HR=0.452。
  • 早期反应者中位PFS 7.41个月 vs 非反应者5.37个月(log-rank P=0.0167)。
  • 10周RECIST反应与OS独立相关,HR=0.484(95%CI 0.275-0.852)。

核心结论

  • 基于PET-CT和CTC分析的早期反应在转移性结直肠癌一线化疗患者中具有预后意义和可能的预测意义。
  • 其作为评估早期药物反应新工具的效用尚需进一步验证。

研究设计与样本

  • 前瞻性评估研究,纳入84例接受一线化疗的转移性结直肠癌患者,中位随访32.9个月(95%CI 24.5个月-未达到),70例(84.3%)完成所有评估。
  • 基线及化疗开始后4-6周行PET-CT和CTC分析,10-12周行CT扫描评估RECIST反应。
  • 早期反应定义为化疗开始后4-6周达到双终点:PET-CT(靶病灶SUVmax总和下降30%)和CTC反应(CTC<3个/7.5ml血)。

主要发现

  • 双终点早期反应与PFS独立相关(HR=0.452,95%CI 0.267-0.765)。
  • 早期反应者中位PFS为7.41个月(95%CI 6.05-9.11),非反应者为5.37个月(95%CI 4.68-6.24),log-rank P=0.0167。
  • 10周RECIST反应与OS独立相关(HR=0.484,95%CI 0.275-0.852)。
  • 双终点早期反应预测后续RECIST反应的敏感性、特异性和阳性预测值分别为64%、70%和74%。

关键数值与推荐

  • 早期反应双终点:PET-CT靶病灶SUVmax总和下降30%且CTC<3个/7.5ml血(化疗开始后4-6周)。
  • RECIST反应评估于10-12周进行。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated the predictive and prognostic significance of assessing early drug response with both positron-emission computerized tomography (PET-CT) and circulating tumor cells (CTCs) in patients receiving first-line chemotherapy for metastatic colorectal cancer. PATIENTS AND METHODS: Eligible patients had PET-CT and CTC analysis at baseline and 4-6 weeks after starting chemotherapy, and then a CT scan at 10-12 weeks to assess the Response Evaluation Criteria In Solid Tumors (RECIST) response. Early response was defined as achieving a dual-endpoint consisting of PET-CT (30% drop in the sum of maximum standard uptake values-SUVmax-of target lesions) and CTC response (CTC < 3 cells/7.5 ml blood) at 4-6 weeks after starting chemotherapy. RESULTS: About 84 patients were enrolled with a median follow-up of 32.9 months (95% confidence interval, CI, 24.5 months-not reached, NR), and 70 patients (84.3%) completed all assessments. Achieving an early response based on the dual-endpoint was independently associated with progression-free survival (hazard ratio, HR = 0.452, 95% CI 0.267-0.765). The median progression-free survival of early responders was 7.41 months (95% CI, 6.05-9.11) compared with 5.37 months (95% CI, 4.68-6.24) in non-responders (log-rank, P = 0.0167). RECIST response at 10 weeks was independently associated with overall survival (OS) (HR = 0.484, 95% CI, 0.275-0.852). Early response based on the dual-endpoint could predict the subsequent RECIST response with a sensitivity, specificity and positive predictive value of 64%, 70% and 74%, respectively. CONCLUSIONS: Early response based on both PET-CT and CTC analysis has prognostic and probably predictive significance in patients undergoing first-line chemotherapy for metastatic colorectal cancer. Its utility as a new tool for assessing early drug response should be further validated.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ma B, King AD, Leung L, et al. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. Ann Oncol. 2017. PMID: 28379285. doi:10.1093/annonc/mdx149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。